KRYS Krystal Biotech Inc
- Stocks
- Healthcare
- NASDAQ: KRYS
Price (delayed)
$199.88
Market cap
$5.8B
P/E Ratio
28.97
Dividend/share
N/A
EPS
$6.9
Enterprise value
$5.41B
Relative Growth:
Rel. Growth:
74
Relative Strength:
Rel. Strength:
80
Relative Valuation:
Rel. Valuation:
55
Relative Profitability:
Rel. Profitability:
99
Krystal Biotech, Inc. is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases.
Highlights
The gross profit has soared by 57% YoY and by 4.9% QoQ
The revenue has surged by 55% year-on-year and by 3.9% since the previous quarter
The debt has grown by 27% YoY
Key stats
What are the main financial stats of KRYS
Market
Valuations
Earnings
Shares outstanding
29M
Market cap
$5.8B
Enterprise value
$5.41B
Price to earnings (P/E)
28.97
Price to book (P/B)
5.08
Price to sales (P/S)
15.51
PEG
0.11
EV/EBIT
28.95
EV/EBITDA
28
EV/Sales
14.51
Revenue
$373.16M
Gross profit
$351.76M
Operating income
$158.24M
Net income
$198.91M
EBIT
$186.95M
EBITDA
$193.29M
Free cash flow
$166.02M
Per share
Balance sheet
Liquidity
EPS
$6.9
EPS diluted
$6.68
Free cash flow per share
$5.73
Book value per share
$39.31
Revenue per share
$12.89
TBVPS
$42.83
Total assets
$1.24B
Total liabilities
$102.22M
Debt
$9.51M
Equity
$1.14B
Working capital
$834.38M
Debt to equity
0.01
Current ratio
10.14
Quick ratio
9.43
Net debt/EBITDA
-1.98
Margins
Efficiency
Dividend
EBITDA margin
51.8%
Gross margin
94.3%
Net margin
53.3%
Operating margin
42.4%
Return on assets
17.6%
Return on equity
19.4%
Return on invested capital
26.8%
Return on capital employed
16.3%
Return on sales
50.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KRYS stock price
How has the Krystal Biotech stock price performed over time
Intraday
-1.66%
1 week
8.01%
1 month
9.01%
1 year
14.6%
YTD
27.59%
QTD
13.23%
Financial performance
How have Krystal Biotech's revenue and profit performed over time
Revenue
$373.16M
Gross profit
$351.76M
Operating income
$158.24M
Net income
$198.91M
Gross margin
94.3%
Net margin
53.3%
The net margin has soared by 146% YoY and by 31% from the previous quarter
The gross profit has soared by 57% YoY and by 4.9% QoQ
The revenue has surged by 55% year-on-year and by 3.9% since the previous quarter
The net income has grown by 36% from the previous quarter
Price vs fundamentals
How does KRYS's price correlate with its fundamentals
Growth
What is Krystal Biotech's growth rate over time
Valuation
What is Krystal Biotech stock price valuation
P/E
28.97
P/B
5.08
P/S
15.51
EV/EBIT
28.95
EV/EBITDA
28
EV/Sales
14.51
The EPS has grown by 35% from the previous quarter
KRYS's price to earnings (P/E) is 20% lower than its last 4 quarters average of 36.1
Krystal Biotech's equity has increased by 28% YoY and by 9% QoQ
KRYS's P/B is 21% above its 5-year quarterly average of 4.2 and 10% above its last 4 quarters average of 4.6
The revenue has surged by 55% year-on-year and by 3.9% since the previous quarter
The P/S is 12% above the last 4 quarters average of 13.9
Efficiency
How efficient is Krystal Biotech business performance
Krystal Biotech's ROA has soared by 198% YoY and by 28% from the previous quarter
Krystal Biotech's return on invested capital has surged by 125% YoY
The ROS has soared by 111% YoY and by 7% from the previous quarter
The ROE has grown by 28% from the previous quarter
Dividends
What is KRYS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KRYS.
Financial health
How did Krystal Biotech financials performed over time
The current ratio is up by 27% year-on-year and by 4.8% since the previous quarter
The company's total assets rose by 26% YoY and by 9% QoQ
The debt is 99% less than the equity
Krystal Biotech's equity has increased by 28% YoY and by 9% QoQ
The debt has grown by 27% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.